Cytek BiosciencesCTKB -3.94%71 Cash Ratio is 3.24 as of Mar. 2026, which is 39% below its 10-year median of 5.29. GuruFocus rates CTKB with a GF Score™ of 71/100 and a GF Value™ of $5.83 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 842 Medical Devices & Instruments companies, Cytek Biosciences ranks better than 79.1% on this metric.
Cytek Biosciences has a Cash Ratio of 3.24. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Cytek Biosciences's Cash Ratio or its related term are showing as below:
CTKB'
s Cash Ratio Range Over the Past 10 Years
Min: 1.43 Med: 5.29 Max: 12.55
Current: 3.24
During the past 7 years, Cytek Biosciences's highest Cash Ratio was 12.55. The lowest was 1.43. And the median was 5.29.
CTKB's Cash Ratio is ranked better than 79.1% of 842
companies
in the Medical Devices & Instruments industry
Industry Median: 0.97
vs CTKB: 3.24
Cytek Biosciences (NAS:CTKB) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Cytek Biosciences Cash Ratio Related Terms
Cytek Biosciences Cash Ratio Historical Data
* Premium members only.
The historical data trend for Cytek Biosciences's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Cytek Biosciences's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cytek Biosciences Cash Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Cytek Biosciences's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Cytek Biosciences's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cytek Biosciences (CTKB) has a Cash Ratio of 3.24 as of Mar. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Cytek Biosciences and its competitors. This is 39% below median its historical median of 5.29. Over the past decade, Cytek Biosciences' Cash Ratio has ranged from 1.43 to 12.55. According to the industry distribution chart, Cytek Biosciences ranks #176 out of 842 companies in the Medical Devices & Instruments industry, placing it in the top 20.9%.
Is Cytek Biosciences' Cash Ratio too high?
Cytek Biosciences' current Cash Ratio of 3.24 is 39% below median its 10-year median of 5.29. Over the past 10 years, this metric has ranged from a low of 1.43 to a high of 12.55. The Medical Devices & Instruments industry median Cash Ratio is 0.97. Cytek Biosciences' value of 3.24 is 234% above this industry median. Based on the distribution chart, Cytek Biosciences ranks #176 out of 842 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Cytek Biosciences has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cytek Biosciences' Cash Ratio compare to CERS and NPCE?
According to the Medical Devices & Instruments industry distribution chart, Cytek Biosciences ranks #176 out of 842 companies for Cash Ratio. This places Cytek Biosciences in the top 21% of its industry — outperforming the majority of peers. The industry median Cash Ratio is 0.97. Cytek Biosciences' value of 3.24 is 234% above this benchmark. Historically, Cytek Biosciences' own Cash Ratio has ranged from 1.43 to 12.55 over the past decade. While the company's 10-year median is 5.29 vs. the industry median of 0.97, Cytek Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Medical Devices & Instruments company?
The median Cash Ratio among Medical Devices & Instruments companies is 0.97, based on 842 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cytek Biosciences's current Cash Ratio of 3.24 is 234% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Cytek Biosciences and its competitors. For the Medical Devices & Instruments industry, the median Cash Ratio is 0.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cytek Biosciences's current Cash Ratio is 3.24, which is 39% below median its own 10-year median of 5.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cytek Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Cytek Biosciences (CTKB) is currently considered Modestly Undervalued. The stock's GF Value™ is $5.83, compared to a current price of $4.39 — trading 24.7% below its estimated fair value. The current Cash Ratio is 3.24, which is 39% below median its 10-year median of 5.29 and 234% above the Medical Devices & Instruments industry median of 0.97. Cytek Biosciences' overall GF Score™ is 71/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Cytek Biosciences (CTKB), the current Cash Ratio is 3.24 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cytek Biosciences (CTKB) Overvalued in 2026?
Based on GuruFocus' analysis, Cytek Biosciences stock appears to be undervalued.
The current stock price of $4.39 is trading 24.7% below its estimated GF Value™ of $5.83.
GuruFocus considers Cytek Biosciences to be Modestly Undervalued.
Key valuation signals for CTKB:
Cash Ratio: 3.24 (39% below median its 10-year median of 5.29)
GF Value™: $5.83 vs. price of $4.39 (24.7% below fair value)
Industry Position: 234% above the Medical Devices & Instruments median (#176 of 842)
No single metric tells the full story. See the CTKB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of research and clinical tools with its novel technical approach of leveraging the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its patented FSP technology optimizes sensitivity and accuracy through its optical and electronic designs that utilize an inventive method of light detection and distribution to a specifically selected number and type of detectors. Its FSP cell analyzers, the Cytek Aurora, Northern Lights, and Cytek Aurora Evo systems, deliver high-resolution, high-content and high-sensitivity cell analysis and address the inherent limitations of other technologies.
71GF Score
Get the complete analysis for CTKB
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CTKB has been successfully added to your 
